Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
Clinical trial NCT05539118 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05539118
- Sponsor
- Xijing Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-30
- Primary completion
- 2024-12-31
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.